Healthcare / Medical DevicesTSXV
$0.19
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-1.4M · quality 64.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
18/100
F
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
12/100
SEC 0%
Sin guardar todavía.
Market Cap
$13M
P/E
N/A
•EV/EBITDA
N/A
•ROE
16.3%
↑Gross Margin
76.0%
↑Debt/Equity
-0.99
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2024 · 2 años de histórico normalizado
Revenue CAGR
+146.5%
FCF CAGR
—
FCF margin
-185.2%
FCF / Net income
0.88x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $492000.0 · net income $-1.0M · FCF $-911000.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | $492000.00 | $492000.00 | $41000.00 | $81000.00 |
| Net Income | $-1.0M | $-1.0M | $-2.2M | $-2.6M |
| EBITDA | $-537000.00 | $-537000.00 | $-1.8M | $-2.3M |
| EPS | -0.02 | -0.02 | -0.03 | -0.04 |
| Gross Margin | 76.0% | 76.0% | 12.2% | 8.6% |
| Operating Margin | -222.8% | -222.8% | -4256.1% | -2779.0% |
| Net Margin | -211.4% | -211.4% | -5356.1% | -3202.5% |
| Balance Sheet | ||||
| Debt/Equity | -0.99 | -0.99 | -0.95 | -0.95 |
| Current Ratio | 0.76 | 0.76 | — | — |
| Cash Flow | ||||
| Free Cash Flow | $-911000.00 | $-911000.00 | $-1.4M | $-1.9M |
| Returns | ||||
| ROE | 16.3% | 16.3% | 41.0% | 73.3% |
| Growth & Yield | ||||
| Revenue Growth | 1100.0% | 1100.0% | -49.4% | — |
| EPS Growth | 52.6% | 52.6% | 15.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-74.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.03 → -0.02
Residual
-74.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.